British journal of haematology · 2026
The impact of scaRNA12 deregulation on p53-mediated cellular stress response in B-cell precursor acute lymphoblastic leukaemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Verbeek Martijn W C, Sanders Mathijs A, Grashof Dwin G B, Hoogenboezem Remco M, van Zuijen Iris, Bos Annemarieke, van Gulck Trui, Olsman Rosan, Mukhopadhyay Rishov, Bindels Eric M J, Valk Peter J M, van de Werken Harmen J G, van der Velden Vincent H J, Erkeland Stefan J
Аннотация
Small nucleolar ribonucleic acids (snoRNAs) are a class of small non-coding RNAs involved in the post-transcriptional modification of ribosomal RNAs (rRNA) and small nuclear RNAs (snRNA). Mounting evidence indicates that specific snoRNAs are drivers of oncogenesis, but their role in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is unknown. We found that a small subset of 30 snoRNAs is commonly deregulated in BCP-ALL. Small Cajal body-specific RNA 12 (scaRNA12) was the strongest downregulated snoRNAs in BCP-ALL. Forced expression of scaRNA12 in BCP-ALL cells largely recovered the level of uridine-46 pseudouridylation of U5 snRNA (U5:Ψ46), an important RNA modification for proper splicing and gene expression regulation. We found that scaRNA12 controls a set of genes that belong to pathways that are frequently affected in BCP-ALL samples. We show that scaRNA12 activates p53, which is commonly affected in BCP-ALL even in the absence of p53 mutations. We show that scaRNA12 expression decreased the expression of upstream p53 regulators and provide novel evidence for a role of scaRNA12 in p53 regulation. We found that forced expression of scaRNA12 in BCP-ALL increased p53 activity and significantly enhanced the sensitivity of BCP-ALL to chemotherapeutic reagents. Together, our results suggest a tumour-suppressing role for scaRNA12 in BCP-ALL.